关键信息
-
基因名
CFX
- 应用
-
别名
CFX；sms；DNA repair Protein RadA
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P24554
-
表达区间
1-460aa
-
氨基酸序列
MAKAPKRAFVCNECGADYPRWQGQCSACHAWNTITEVRLAASPMVARNERLSGYAGSAGVAKVQKLSDISLEELPRFSTGFKEFDRVLGGGVVPGSAILIGGNPGAGKSTLLLQTLCKLAQQMKTLYVTGEESLQQVAMRAHRLGLPTDNLNMLSETSIEQICLIAEEEQPKLMVIDSIQVMHMADVQSSPGSVAQVRETAAYLTRFAKTRGVAIVMVGHVTKDGSLAGPKVLEHCIDCSVLLDGDADSRFRTLRSHKNRFGAVNELGVFAMTEQGLREVSNPSAIFLSRGDEVTSGSSVMVVWEGTRPLLVEIQALVDHSMMANPRRVAVGLEQNRLAILLAVLHRHGGLQMADQDVFVNVVGGVKVTETSADLALLLAMVSSLRDRPLPQDLVVFGEVGLAGEIRPVPSGQERISEAAKHGFRRAIVPAANVPKKAPEGMQIFGVKKLSDALSVFDDL
-
分子量
49.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CFX, or Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, plays a crucial role in maintaining the balance of salt and water on epithelial surfaces in various organs, particularly the lungs and pancreas. Mutations in the CFTR gene can lead to cystic fibrosis, a genetic disorder characterized by thick mucus buildup, leading to severe respiratory and digestive issues. Research into CFX recombinant proteins aims to better understand the structure and function of CFTR, facilitate the development of therapies to restore its function, and explore innovative approaches for treating cystic fibrosis. Recombinant proteins can be engineered to study specific aspects of CFTR and to test potential drugs that might correct defective CFTR proteins or enhance their function. As scientists delve into the complexities of CFTR's mechanisms and interactions within the cellular environment, this research not only sheds light on the pathophysiology of cystic fibrosis but also paves the way for novel therapeutic strategies, potentially improving the quality of life for patients affected by this condition. The ongoing studies seek to evaluate the efficacy of small molecule correctors and potentiators that target various CFTR mutations, thus broadening the therapeutic horizon for cystic fibrosis.
